Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Purple Biotech (PPBT) Cash & Current Investments (2016 - 2025)

Purple Biotech has reported Cash & Current Investments over the past 7 years, most recently at $15.5 million for Q4 2022.

  • Quarterly Cash & Current Investments fell 67.24% to $15.5 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2022, down 67.24% year-over-year, with the annual reading at $15.5 million for FY2022, 67.49% down from the prior year.
  • Cash & Current Investments was $15.5 million for Q4 2022 at Purple Biotech, down from $32.9 million in the prior quarter.
  • Over five years, Cash & Current Investments peaked at $57.8 million in Q4 2020 and troughed at $4.4 million in Q2 2020.
  • The 5-year median for Cash & Current Investments is $32.9 million (2022), against an average of $29.5 million.
  • Year-over-year, Cash & Current Investments surged 1000.93% in 2021 and then crashed 67.24% in 2022.
  • A 5-year view of Cash & Current Investments shows it stood at $6.7 million in 2018, then dropped by 4.47% to $6.4 million in 2019, then skyrocketed by 805.32% to $57.8 million in 2020, then dropped by 18.35% to $47.2 million in 2021, then crashed by 67.24% to $15.5 million in 2022.
  • Per Business Quant, the three most recent readings for PPBT's Cash & Current Investments are $15.5 million (Q4 2022), $32.9 million (Q3 2022), and $32.9 million (Q2 2022).